Drug Profile
Aloxistatin
Alternative Names: E 64 D; EST; Estate; Loxistatin; RexostatineLatest Information Update: 03 Apr 1996
Price :
$50
*
At a glance
- Originator Taisho Pharmaceutical
- Developer Sumitomo Pharmaceuticals; Taisho Pharmaceutical
- Class Antineoplastics; Eye disorder therapies
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Muscular dystrophies
Most Recent Events
- 03 Apr 1996 Discontinued-Clinical for Muscular dystrophy in Japan (Unknown route)
- 28 Mar 1996 Investigation in Muscular dystrophy in Japan (Unknown route)